Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines

Research output: Contribution to journalArticle

296 Citations (Scopus)

Abstract

NMDA and non-NMDA (AMPA/kainate) antagonists have potential in the treatment of a diverse group of neurological disorders associated with excessive activation of excitatory amino acid receptors. Here Michael Rogawski reviews recent progress in the development of therapeutically useful NMDA receptor channel blockers and a new class of selective AMPA/ kainate receptor antagonists, the 2,3-benzodiazepines. Research on these novel noncompetitive excitatory amino acid antagonists has opened promising new avenues for the development of drugs to treat epilepsy, ischaemia, neuro-degeneration and Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)325-331
Number of pages7
JournalTrends in Pharmacological Sciences
Volume14
Issue number9
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Aminoacylation
Kainic Acid Receptors
Excitatory Amino Acid Antagonists
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
AMPA Receptors
Kainic Acid
Glutamate Receptors
N-Methylaspartate
Nervous System Diseases
N-Methyl-D-Aspartate Receptors
Benzodiazepines
Parkinson Disease
Epilepsy
Ischemia
Research
Pharmaceutical Preparations
Chemical activation
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

@article{a970adac34fd43c4925359667410e62a,
title = "Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines",
abstract = "NMDA and non-NMDA (AMPA/kainate) antagonists have potential in the treatment of a diverse group of neurological disorders associated with excessive activation of excitatory amino acid receptors. Here Michael Rogawski reviews recent progress in the development of therapeutically useful NMDA receptor channel blockers and a new class of selective AMPA/ kainate receptor antagonists, the 2,3-benzodiazepines. Research on these novel noncompetitive excitatory amino acid antagonists has opened promising new avenues for the development of drugs to treat epilepsy, ischaemia, neuro-degeneration and Parkinson's disease.",
author = "Rogawski, {Michael A}",
year = "1993",
doi = "10.1016/0165-6147(93)90005-5",
language = "English (US)",
volume = "14",
pages = "325--331",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Therapeutic potential of excitatory amino acid antagonists

T2 - channel blockers and 2,3-benzodiazepines

AU - Rogawski, Michael A

PY - 1993

Y1 - 1993

N2 - NMDA and non-NMDA (AMPA/kainate) antagonists have potential in the treatment of a diverse group of neurological disorders associated with excessive activation of excitatory amino acid receptors. Here Michael Rogawski reviews recent progress in the development of therapeutically useful NMDA receptor channel blockers and a new class of selective AMPA/ kainate receptor antagonists, the 2,3-benzodiazepines. Research on these novel noncompetitive excitatory amino acid antagonists has opened promising new avenues for the development of drugs to treat epilepsy, ischaemia, neuro-degeneration and Parkinson's disease.

AB - NMDA and non-NMDA (AMPA/kainate) antagonists have potential in the treatment of a diverse group of neurological disorders associated with excessive activation of excitatory amino acid receptors. Here Michael Rogawski reviews recent progress in the development of therapeutically useful NMDA receptor channel blockers and a new class of selective AMPA/ kainate receptor antagonists, the 2,3-benzodiazepines. Research on these novel noncompetitive excitatory amino acid antagonists has opened promising new avenues for the development of drugs to treat epilepsy, ischaemia, neuro-degeneration and Parkinson's disease.

UR - http://www.scopus.com/inward/record.url?scp=0027176541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027176541&partnerID=8YFLogxK

U2 - 10.1016/0165-6147(93)90005-5

DO - 10.1016/0165-6147(93)90005-5

M3 - Article

C2 - 7504360

AN - SCOPUS:0027176541

VL - 14

SP - 325

EP - 331

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 9

ER -